Ultromics is a cutting-edge health technology company specializing in AI-driven cardiology diagnostics. Founded in 2017, the company is an offshoot of the University of Oxford, where it originated to transform cardiac imaging through advanced technologies. Ultromics has raised significant capital, with a recent Series C funding round totaling $55 million, supporting its expansion and innovation efforts. The company is headquartered in Oxford, UK, and was co-founded by Dr. Ross Upton and Professor Paul Leeson.
In recent years, Ultromics has made significant advances that reinforce its position as a pioneer in the medical technology space, particularly in AI applications for cardiology.
| Attribute | Information |
|---|---|
| Founding Date | 2017 |
| Headquarters | Oxford, UK |
| Founders | Dr. Ross Upton, Professor Paul Leeson |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Legal & General, Allegis Capital, Lightrock, Oxford Science Enterprises, GV |
| Industry | Medical Technology |
| Number of Employees | Not publicly disclosed |
Ultromics was established as a spin-out from the University of Oxford in 2017, leveraging cutting-edge research in applying artificial intelligence to cardiac imaging. The company emerged from a collaboration between its founders and the UK's National Health Service (NHS), aiming to overcome the limitations of traditional echocardiography. This collaboration gave rise to EchoGo, Ultromics' flagship platform, which automates the analysis of echocardiograms using AI to enhance diagnostic precision. The early groundwork laid by the founders, combined with financial backing from Oxford Sciences Innovation, a key player in converting academic research into viable businesses, enabled Ultromics to position itself as a leader in the AI-driven cardiac diagnostics field.
Ultromics operates on a unique business model that integrates AI technology with medical imaging processes to deliver innovative diagnostic solutions. Its EchoGo platform stands as the first FDA-cleared, AI-powered echocardiography solution that offers unprecedented accuracy in detecting heart conditions traditionally obscure to clinicians.
Ultromics has significantly strengthened its market position in recent years, focusing on U.S. expansion and product diversification. The need for non-invasive, accurate diagnostic solutions culminated in its EchoGo platform, which now includes probability scoring for heart failure and tools for detecting heart disease precursors. Ultromics’ AI technology enhances echocardiogram analysis without altering existing workflows, offering hospitals a seamless integration of cutting-edge diagnostics. Presently, the company is considered an innovator in the AI health tech sector, offering solutions that serve a large, underserved cardiovascular disease market.
Ultromics embodies a transformative force in medical diagnostics, particularly for cardiology, through its pioneering AI technologies. By streamlining the detection of elusive heart conditions like HFpEF and cardiac amyloidosis, Ultromics is reshaping how clinicians approach diagnostics. Its trajectory, supported by robust funding and strategic partnerships, indicates a promising future where technology enables earlier and more precise medical interventions, potentially reducing the global burden of cardiovascular diseases.